Jens Freiberg‐Richter

1.6k total citations
27 papers, 752 citations indexed

About

Jens Freiberg‐Richter is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jens Freiberg‐Richter has authored 27 papers receiving a total of 752 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Hematology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jens Freiberg‐Richter's work include Colorectal Cancer Treatments and Studies (9 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Jens Freiberg‐Richter is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Jens Freiberg‐Richter collaborates with scholars based in Germany and Latvia. Jens Freiberg‐Richter's co-authors include Gerhard Ehninger, Uwe Platzbecker, Eberhard Schleyer, Martin Bornhäuser, Uta Oelschlägel, Thomas Illmer, Malte von Bonin, Stefan Pursche, Markus Schaich and Tracy L. Bergemann and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Jens Freiberg‐Richter

27 papers receiving 729 citations

Peers

Countries citing papers authored by Jens Freiberg‐Richter

Since Specialization

Citations

This map shows the geographic impact of Jens Freiberg‐Richter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Freiberg‐Richter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Freiberg‐Richter more than expected).

Fields of papers citing papers by Jens Freiberg‐Richter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Freiberg‐Richter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Freiberg‐Richter. The network helps show where Jens Freiberg‐Richter may publish in the future.

Co-authorship network of co-authors of Jens Freiberg‐Richter

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Freiberg‐Richter. A scholar is included among the top collaborators of Jens Freiberg‐Richter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Freiberg‐Richter. Jens Freiberg‐Richter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial 2022 ·Frontiers in Oncology ·Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg‐Richter, (unknown), Claudio Denzlinger, Ullrich Graeven, Kathrin Heinrich, Swantje Held, Arndt Stahler, (unknown), Ivan Jelas, Jobst C. von Einem, Sebastian Stintzing, Clemens Gießen-Jung, Dominik Paul Modest	2
2	Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110) 2021 ·European Journal of Cancer ·Kathrin Heinrich, Dominik Paul Modest, Ingrid Ricard, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Ullrich Graeven, Jens Uhlig, Michael Schenk, Jens Freiberg‐Richter, (unknown), Claudio Denzlinger, Clemens Gießen-Jung, Arndt Stahler, Marlies Michl, Swantje Held, Andreas Jung, Thomas Kirchner, Sebastian Stintzing, Volker Heinemann	8
3	Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study) 2020 ·European Journal of Cancer ·Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg‐Richter, (unknown), Claudio Denzlinger, Ullrich Graeven, Ingo Schwaner, Arndt Stahler, Kathrin Heinrich, Andreas Jung, Swantje Held, Jobst C. von Einem, Sebastian Stintzing, Clemens Gießen-Jung, Dominik Paul Modest	6
4	Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’ 2018 ·European Journal of Cancer ·Michael Haas, Jens T. Siveke, Michael Schenk, Markus M. Lerch, K Caca, Jens Freiberg‐Richter, Ludwig Fischer von Weikersthal, Frank Kullmann, A. Reinacher-Schick, Martin Fuchs, S Kanzler, Volker Kunzmann, Thomas J. Ettrich, Stephan Krüger, C. Benedikt Westphalen, Swantje Held, Volker Heinemann, Stefan Boeck	23
5	Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study. 2017 ·Annals of Oncology ·Dominik Paul Modest, (unknown), Thomas Decker, Ursula Vehling‐Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg‐Richter, (unknown), Claudio Denzlinger, (unknown), Ullrich Graeven, Gunter Schuch, Ingo Schwaner, Arndt Stahler, Andreas Jung, Swantje Held, Sebastian Stintzing, Clemens Gießen-Jung, Volker Heinemann	4
6	IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial. 2015 ·Journal of Clinical Oncology ·Uğur Şahin, Salah‐Eddin Al‐Batran, Wael Hozaeel, Zanete Zvirbule, Jens Freiberg‐Richter, Florian Lordick, Marianne Just, Michael Bitzer, Peter Thuss‐Patience, (unknown), Volker Brass, Christian Mueller, (unknown), (unknown)	17
7	A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial 2011 ·BMC Cancer ·Clemens Gießen, Ludwig Fischer von Weikersthal, Axel Hinke, Sebastian Stintzing, Frank Kullmann, Ursula Vehling‐Kaiser, Julia Mayerle, Markus Bangerter, Claudio Denzlinger, Markus Sieber, Christian Teschendorf, Jens Freiberg‐Richter, Christoph Schulz, Dominik Paul Modest, Nicolas Moosmann, (unknown), Volker Heinemann	7
8	Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation 2008 ·Bone Marrow Transplantation ·(unknown), Jens Freiberg‐Richter, Uwe Platzbecker, Alexander Kiani, Johannes Schetelig, Thomas Illmer, Gerhard Ehninger, Eberhard Schleyer, Martin Bornhäuser	31
9	Accidental busulfan overdose during conditioning for stem cell transplantation 2004 ·Bone Marrow Transplantation ·Andreas Jenke, Jens Freiberg‐Richter, Stefan Wilhelm, Mathias Freund, Ulf Renner, Martin Bornhäuser, Eberhard Schleyer, Gerhard Ehninger, Ulrich S. Schuler	9
10	CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid 2004 ·Annals of Hematology ·Martin Bornhäuser, Andreas Jenke, Jens Freiberg‐Richter, (unknown), Ulrich S. Schuler, Brigitte Mohr, Gerhard Ehninger, Eberhard Schleyer	38
11	P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate 2004 ·Leukemia ·Thomas Illmer, Markus Schaich, Uwe Platzbecker, Jens Freiberg‐Richter, Uta Oelschlägel, Malte von Bonin, Stefan Pursche, Tracy L. Bergemann, Gerhard Ehninger, Eberhard Schleyer	242
12	Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations 2003 ·Journal of Chromatography B ·Eberhard Schleyer, Stefan Pursche, C.-H. Köhne, Ulrich S. Schuler, Ulf Renner, Harald Gschaidmeier, Jens Freiberg‐Richter, (unknown), Andreas Jenke, Malte von Bonin	40
13	Double lumen port access in patients receiving allogeneic blood stem cell transplantation 2001 ·Bone Marrow Transplantation ·Uwe Platzbecker, Thomas Illmer, Markus Schaich, Jens Freiberg‐Richter, A Helwig, (unknown), Andreas Jenke, Gerhard Ehninger, Martin Bornhäuser	8
14	Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation 2001 ·Clinical Transplantation ·Andreas Jenke, Ulf Renner, (unknown), Jens Freiberg‐Richter, Uwe Platzbecker, A Helwig, (unknown), K. Schäfer-Eckart, Gerhard Ehninger, Martin Bornhäuser	39
15	SUCCESSFUL PREEMPTIVE CIDOFOVIR TREATMENT FOR CMV ANTIGENEMIA AFTER DOSE-REDUCED CONDITIONING AND ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION 2001 ·Transplantation ·Uwe Platzbecker, (unknown), Christian Thiede, A Helwig, Jens Freiberg‐Richter, Ulrich S. Schuler, (unknown), (unknown), Axel Rethwilm, Gerhard Ehninger, (unknown)	31
16	Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF 2001 ·Annals of Hematology ·Uwe Platzbecker, Christian Thiede, Jens Freiberg‐Richter, A Helwig, Brigitte Mohr, (unknown), Monika Füssel, Thomas Köhler, Gerhard Ehninger, Martin Bornhäuser	13
17	Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia 2001 ·Bone Marrow Transplantation ·Uwe Platzbecker, Christian Thiede, Jens Freiberg‐Richter, Christoph Röllig, A Helwig, Ulrike Schäkel, Brigitte Mohr, Markus Schaich, Gerhard Ehninger, Martin Bornhäuser	8
18	Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals 2001 ·Cancer Genetics and Cytogenetics ·Brigitte Mohr, Martin Bornhäuser, Uwe Platzbecker, Jens Freiberg‐Richter, (unknown), Gabriele Prange‐Krex, (unknown), Frank Kroschinsky, Gerhard Ehninger, Christian Thiede	11
19	Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. 2001 ·PubMed ·Martin Bornhäuser, Christian Thiede, Uwe Platzbecker, Andreas Jenke, A Helwig, (unknown), Jens Freiberg‐Richter, Christoph Röllig, G Geissler, (unknown), Uta Oelschlägel, Gerhard Ehninger	86
20	Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin 2000 ·Bone Marrow Transplantation ·Martin Bornhäuser, Christian Thiede, Ulrich S. Schuler, Uwe Platzbecker, Jens Freiberg‐Richter, A Helwig, (unknown), Christoph Röllig, Ralph Naumann, Frank Kroschinsky, Andreas Neubauer, Gerhard Ehninger	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact